Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 ...

Important Safety Information: EYLEA HD and EYLEA are administered via intravitreal injection. Patients should not use EYLEA HD if they have ocular or periocular infections, active intraocular ...

The incidence of mild intraocular inflammation (IOI) in the real world occurs more frequently after intravitreal injection of ...

Intraocular inflammation occurred more frequently with 8-mg aflibercept (Eylea) compared with what ... Today that "inflammation after intravitreal injections can sometimes be from endophthalmitis ...

It is highly similar to the reference product Eylea® (aflibercept ... with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed ...

EYLEA HD was developed to achieve comparable efficacy and safety to EYLEA, but with fewer injections. EYLEA HD is supported by a robust body of research and is currently approved in the U.S. to ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period, reducing the number of injections by half ...

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...